Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:57 AM
Ignite Modification Date:
2025-12-25 @ 3:57 AM
NCT ID:
NCT04032002
Eligibility Criteria:
Inclusion Criteria (patients):
* Patient with inherited bradykinic angioedema due to quantitative or qualitative C1-inhibitor deficiencies, regardless of the frequency or severity of seizures and regardless of their background treatment, with the following diagnostic criteria:
* C1-inhibitor rate \<50% of normal
* Repeated episodes characteristic of bradykinic angioedema
* Hereditary nature of the disease.
* Person who read and understood the newsletter and signed the consent form
* Person affiliated with a social security scheme
* Effective contraception in women of childbearing age (negative pregnancy test). For postmenopausal women, a confirmatory diagnosis should be obtained (amenorrhea for at least 12 months before the inclusion visit).
Inclusion Criteria (volunteers):
* Person affiliated with a social security scheme
* Person who read and understood the newsletter and signed the consent form
* Effective contraception in women of childbearing age (negative pregnancy test). For postmenopausal women, a confirmation diagnosis should be obtained (amenorrhea for at least 12 months before the inclusion visit)
Exclusion Criteria (patients):
* Angioedema crisis less than 1 month old
* Chronic inflammatory disease such as rheumatoid arthritis or Crohn's disease.
* Acute infection in progress, with or without anti-infectious treatment
* Contraindication to the use of trinitrin:
* Hypersensitivity to nitrates or to any of the excipients
* shock, severe hypotension,
* obstructive cardiomyopathy,
* inferior court inferior myocardial infarction with right ventricular extension, except in case of evidence of left ventricular failure,
* intracranial hypertension,
* patient treated with sildenafil
* Pregnant or parturient or breastfeeding woman or lack of proven contraception
* Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship
* Patient participating or having participated in another therapeutic trial within one week.
Exclusion Criteria (volunteers)
* Chronic inflammatory disease such as rheumatoid arthritis or Crohn's disease.
* Acute infection in progress, with or without anti-infectious treatment
* Contraindication to the use of trinitrin:
* Hypersensitivity to nitrates or to any of the excipients
* shock, severe hypotension,
* obstructive cardiomyopathy,
* inferior court inferior myocardial infarction with right ventricular extension, except in case of evidence of left ventricular failure,
* intracranial hypertension,
* patient treated with sildenafil
* Pregnant or parturient or breastfeeding woman or lack of proven contraception
* Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship
* Person participating or having participated in another therapeutic trial within one week.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04032002
Study Brief:
Protocol Section:
NCT04032002